Evotec Se Stock Earnings Reports

Evotec reported 9M 2025 revenues of EUR 535.1m (down 7% YoY) driven by weakness in its Discovery & Preclinical Development (D&PD) business (-12%) while Just‑Evotec Biologics (JEB) grew strongly (+11%). Management highlighted ongoing market headwinds in early-stage biotech (VC funding remains muted) but said operational indicators are improving: proposal volume +20% over the last two quarters and Q3 change‑order dynamics normalizing. The company is ahead on its cost-out program (targeting EUR 60m structural savings for 2025 and pursuing an additional EUR 50m of measures) and continues to realign its organization and commercial capabilities. Evotec signed a transformational transaction with Sandoz (announced Oct 2025) to transfer the Toulouse site and license its continuous manufacturing platform, with initial consideration (~$350m) and potential additional development, milestone and royalty upside (management referenced >$650m of payments and royalties on up to 10 biosimilars). Management reiterated full‑year 2025 guidance: revenues EUR 760–800m and adjusted EBITDA EUR 30–50m, and reiterated mid‑term targets (~8–12% CAGR and >20% EBITDA margin by 2028) while saying revenue CAGR may be toward the lower end but margin potential is stronger. The partnered asset pipeline and AI/NAMs platforms were emphasized as key value drivers: >100 projects, >60% in strategic partnerships, non‑risk‑adjusted milestone potential >EUR 16bn, and management expects up to four partnered molecules in Phase II by 2026. Cash flow trends improved (YTD free cash flow +14% YoY), net debt rose versus Q2 partly due to lease accounting, and closing the Sandoz transaction is expected to materially strengthen liquidity.